Vergelijking

Histrelin vs. Bremelanotide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

220810-26-4

189691-06-3

Molecuulmassa

1323.52 g/mol

1025.18 g/mol

Halfwaardetijd

geen gegevens

2.7 h

Sequentie

geen gegevens

Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Werkingsmechanisme

Histrelin

Continuous GnRH-agonist stimulation downregulates and desensitises the pituitary GnRH receptors — after the initial rise, LH, FSH and the sex hormones fall persistently.

Bremelanotide

Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Histrelin	Bremelanotide
Australië	—	Beperkt
Duitsland	Op recept	Niet goedgekeurd
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Histrelin

Volledige vermelding →

Bremelanotide

Volledige vermelding →

Frequently asked questions

What is the difference between Histrelin and Bremelanotide?: Histrelin is classified as "Onderzoek (overig)", while Bremelanotide is classified as "Onderzoek (overig)". Histrelin: Histrelin is a nonapeptide GnRH agonist delivered as a once-yearly implant. Approved for central precocious puberty in children (Supprelin LA) and advanced prostate cancer (Vantas). Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Histrelin or Bremelanotide?: The highest available evidence level is "Humane RCT" for Histrelin and "Humane RCT" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Histrelin and Bremelanotide in Germany and the United States?: Duitsland: Histrelin — Op recept, Bremelanotide — Niet goedgekeurd. Verenigde Staten: Histrelin — Op recept, Bremelanotide — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Histrelin

Bremelanotide

Australië

—

Beperkt

Duitsland

Op recept

Niet goedgekeurd

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Histrelin and Bremelanotide?

Histrelin is classified as "Onderzoek (overig)", while Bremelanotide is classified as "Onderzoek (overig)". Histrelin: Histrelin is a nonapeptide GnRH agonist delivered as a once-yearly implant. Approved for central precocious puberty in children (Supprelin LA) and advanced prostate cancer (Vantas). Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Histrelin or Bremelanotide?

The highest available evidence level is "Humane RCT" for Histrelin and "Humane RCT" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Histrelin and Bremelanotide in Germany and the United States?

Duitsland: Histrelin — Op recept, Bremelanotide — Niet goedgekeurd. Verenigde Staten: Histrelin — Op recept, Bremelanotide — Op recept. These are factual summaries with source and review date on the individual pages.